Transcriptional Activation of the mrkA Promoter of the Klebsiella pneumoniae Type 3 Fimbrial Operon by the c-di-GMP-Dependent MrkH Protein

The Gram-negative bacterial pathogen Klebsiella pneumoniae forms biofilms to facilitate colonization of biotic and abiotic surfaces. The formation of biofilms by K. pneumoniae requires the expression of type 3 fimbriae: elongate proteinaceous filaments extruded by a chaperone-usher system in the bacterial outer membrane. The expression of the mrkABCDF cluster that encodes this fimbrial system is strongly positively regulated by MrkH, a transcriptional activator that responds to the second messenger, c-di-GMP. In this study, we analyzed the mechanism by which the MrkH protein activates transcriptional initiation from the mrkA promoter. A mutational analysis supported by electrophoretic mobility shift assays demonstrated that a 12-bp palindromic sequence (the MrkH box) centered at −78.5 is the binding site of MrkH. Deletion of half a turn, but not a full turn, of DNA located between the MrkH box and the mrkA promoter destroyed the ability of MrkH to activate mrkA transcription. In addition, a 10-bp AT-rich sequence (the UP element) centered at −63.5 contributed significantly to MrkH-dependent mrkA transcription. In vivo analysis of rpoA mutants showed that the R265 and E273 determinants in the C-terminal domain of RNA polymerase α subunit are needed for MrkH-mediated activation of mrkA transcription. Furthermore, results from mutagenesis of the mrkH gene suggest that the N-terminal region of the protein is involved in transcriptional activation. Taken together, our results suggest that MrkH activates mrkA expression by interacting directly with RNA polymerase, to overcome the inefficient transcriptional initiation caused by the presence of defective core promoter elements.


Introduction
Klebsiella pneumoniae is an opportunistic Gram-negative bacterial pathogen that frequently causes outbreaks of nosocomial pneumonia, catheter-associated urinary tract infections and bacteremia [1,2,3,4,5,6]. K. pneumoniae is able to form robust biofilms which are required for bacterial colonization on indwelling medical devices [7,8,9]. As with numerous other bacteria, biofilm formation of K. pneumoniae requires transduction of chemical signals within the bacterial cells and coordinated transcriptional regulation of the genes involved [10,11,12]. An important physiological change that occurs within bacterial cells during the conversion from planktonic to biofilm life-styles is the enhancement of levels of the second messenger cyclic di-guanosine monophosphate (c-di-GMP) [13,14,15]. Recent studies revealed that c-di-GMP is able to directly modulate the activities of a number of transcriptional regulators that control the expression of genes involved in biofilm formation [16,17,18,19].
K. pneumoniae isolates commonly express two well-characterised fimbrial adhesins, type 1 and type 3 fimbriae [20]. The type 1 fimbriae, which are regulated via phase regulation, have been implicated in promoting K. pneumoniae colonization and biofilm formation [9,21]. Type 3 fimbriae have been shown to mediate the initiation of biofilm formation on biotic and abiotic surfaces, as well as being required for mature biofilm development [7,8,22,23,24]. The various components of type 3 fimbriae are encoded by the mrkABCDF operon [25], which is under the transcriptional control by a single s 70 -dependent promoter located 204 bp upstream from the mrkA major fimbrial subunit gene [10,12]. We have previously shown that transcription from the mrkA promoter is highly up-regulated by MrkH, which exerts 49and 220-fold activation on transcription of the mrkABCDF operon in the haploid and multicopy mrkH background, respectively [10]. MrkH is encoded within a three-locus cluster (mrkH-mrkI-mrkJ) that is located immediately adjacent to the mrkABCDF operon [10]. The mrkI gene encodes a putative regulatory protein that contains a LuxR-like DNA binding domain and is implicated in type 3 fimbriae regulation [10,11]. The mrkJ gene encodes a phosphodiesterase (PDE) that degrades c-di-GMP and functions as a negative regulator of type 3 fimbriae expression and biofilm formation [10,26].
MrkH is a novel transcriptional activator that contains a putative c-di-GMP binding site, referred to as a PilZ domain [10,11]. PilZ domain effector proteins that bind c-di-GMP have been identified in numerous bacteria to relay signals to regulate cellular processes such as motility, exopolysaccharide synthesis and biofilm formation [27]. The PilZ domain contains a characteristic short, flexible loop, which undergoes a conformational change upon c-di-GMP binding [13]. The PilZ family of c-di-GMPbinding proteins includes BcsA, the catalytic a-subunit of cellulose synthase first described in Gluconacetobacter xylinus [28,29]; YcgR, a component of the flagellar machinery found to regulate motility in E. coli [30,31]; and Alg44, a trans-membrane protein that regulates alginate export in Pseudomonas aeruginosa [32]. The BcsA-type and YcgR-type proteins are widespread amongst Gram-negative bacteria. K. pneumoniae possesses cellulose biosynthesis genes, including bcsA. However, as a non-motile organism that lacks flagella, K. pneumoniae does not encode a YcgR homolog.
Mutations within the PilZ domain of the MrkH protein completely destroy its activity, resulting in the loss of ability for K. pneumoniae to produce type 3 fimbriae and biofilms [10,11,12]. Furthermore, using an electrophoretic mobility shift assay (EMSA), we have demonstrated that the binding of MrkH to the mrkA promoter in vitro requires the presence of c-di-GMP, indicating that c-di-GMP is an effector essential for MrkH function [10]. The MrkH-mrkA regulatory system appears to represent one of the most efficiently regulated transcriptional switches in bacteria, but the mode of action of MrkH at its cognate target promoter has not been characterized. In this study, we investigated the mechanism by which MrkH activates mrkA transcription by analyzing the interaction of MrkH with both its DNA target and RNA polymerase.

Bacterial strains, plasmids and growth conditions
The bacterial strains and plasmids used in this study are described in Table S1. K. pneumoniae strain AJ218 (capsule serotype K54) is a human, urinary tract infection isolate [33]. Unless otherwise stated, bacteria were maintained in Luria-Bertani (LB) medium overnight at 37uC with shaking. When appropriate, media were supplemented with antibiotics at the following concentrations: ampicillin, 100 mg/mL; kanamycin, 50 mg/mL; chloramphenicol, 30 mg/mL (for E. coli) and 80 mg/mL (for K. pneumoniae); and trimethoprim, 40 mg/mL.

Site-directed mutagenesis
Mutation in the mrkA promoter region and the mrkH gene were constructed by overlapping-extension PCR [34] of wild-type mrkA and mrkH DNA template using mutagenic oligonucleotides (Table  S2). Overlapping primers were used together with the relevant upstream or downstream complementation primer. Amplified fragments were cloned into the TOPO-TA vector and sequenced. The mutant mrkA fragments were each cloned from the TOPO-TA derivatives into plasmid pMU2385 [35] to create mrkA promoter-lacZ fusions. The mutant mrkH genes were each cloned from the TOPO-TA derivatives into the tet gene of pACYC184 [36].
b-galactosidase assay b-galactosidase activity was assayed as described elsewhere [37]. The overnight cultures of the E. coli MC4100 [38] transformants were diluted 1:25 in LB medium containing appropriate antibiotics and IPTG (0.5 mM) and grown at 37uC to OD 600 = 0.6, after which the b-galactosidase activities were assayed. The data shown are the results of three independent assays.
Expression and purification of the wild type and mutant MrkH-86His proteins The coding regions of the wild type and various mutant mrkH gene flanked by NdeI and BamHI sites were PCR amplified using primer pairs mrkH(NdeI)11a and mrkH(BamHI)11a. The amplified DNA fragments were cloned into TOPO-TA and sequenced. The mrkH fragments encoding the wild type and mutant MrkH proteins with eight histidine residues tagged at the C-terminal end were then excised and cloned into the NdeI and BamHI sites of pET11a (Novagen, Madison, WI) to form pET11a-mrkH-8His. For over-expression of His-tagged proteins, E. coli expression strain BL21(DE3) [39] containing pET11a derivatives was induced with 0.3 mM isopropyl-b-D-thiogalactopyr-anoside (IPTG) for 3 h at 20uC. Over-expressed proteins were purified using Metal Affinity Chromatography.

Electrophoretic mobility shift assay (EMSA)
Primer mrkA116 was labelled at the 59 end with [c-32P]ATP and T4 polynucleotide kinase. The DNA fragments containing the wild type and mutant mrkA regulatory region were generated by PCR using primers 32 P-mrkA116 and mrkA-155, with TOPO-TA derivatives carrying the mrkA promoter fragments (wild-type and mutants) as template. 32 P-labelled mrkA fragments was incubated with varying amounts of purified His-tagged MrkH proteins (wildtype and mutants) with 200 mM c-di-GMP at 30uC for 20 min in the binding buffer (10 mM Tris HCl [pH 7.4], 50 mM KCl, 1 mM DTT, 100 mg/mL BSA and 5 ng/mL poly[dI-dC]). Glycerol was added to a final concentration of 6.5%. Samples were analyzed by electrophoresis on 5% native polyacrylamide gels (37.5:1) containing 50 mM c-di-GMP. Electrophoresis was carried out at room temperature for approximately 8 h at 10 V/ cm.

qrt-RT-PCR
The various K. pneumoniae derivatives were grown in LB until OD 600 = 0.7. Ten milliliters of culture was incubated with 20 ml of RNAprotect solution (Qiagen) at room temperature for 15 min. Cells were pelleted and RNA was purified using a FastRNA Pro Blue Kit (Q-BIOgene). The RNA samples were then treated with DNase I using a RNase-Free DNase Set (Qiagen) before being further purified using the RNeasy MiniElute Cleanup Kit (Qiagen). cDNA synthesis was carried out using Super-script II reverse transcriptase (Invitrogen), Random Primers (Invitrogen) and 10 mg of total RNA as specified by the supplier. Each 25 ml of qrt-RT-PCR reaction contained 10 ng cDNA, 300 nM of the specific primers (Table S2) and 12.5 ml 26 SYBR green master mix (Applied Biosystems). Data were normalized to the K. pneumoniae house-keeping gene rpoD and the relative expression ratio of a target gene was calculated using the method described by Pfaffl [40].

Static biofilm assays
Biofilm assays were performed as described with minor modifications [10,41]. Stationary-phase cells were sub-cultured 1:100 in M63B1-GCAA minimal media (containing 1% glycerol and 0.3% casamino acids) in duplicate 96-well, flat bottom, nontissue culture treated, polystyrene microtiter plates (Nunc, Penfield, NY). Following 24 h static incubation at 37uC, planktonic bacteria were decanted and wells were washed twice with distilled water. Biofilms were stained with 0.1% (wt/vol) crystal violet solution (Sigma-Aldrich), solubilized with 33% acetic acid and subsequently quantified by measuring the optical density at 595 nm. Data shown are the average values of two independent experiments.

Hemagglutination assays
The presence of type 3 fimbriae was determined by mannose resistant hemagglutination (MRHA) assays, as detailed previously [10]. Tannic acid-treated human erythrocytes were mixed with equal volumes of a series of 2-fold dilutions of bacterial suspension with or without 4% D-mannose (Sigma-Aldrich). The minimum bacterial density (CFU/ml) required to agglutinate erythrocytes was measured.

Western blot
MrkH-86His expression (from pACYC184 derivatives) was detected by Western blot analysis using a-His antibody (Dianova, Germany) at a concentration of 1:400. Whole cell lysates were prepared from overnight cultures. Samples were separated by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to Hybond-C Extra nitrocellulose (Amersham Biosciences, Sweden) using a Trans-Blot SD Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA) at 12 V for 30 min. Anti-mouse HRP (Biorad) was used as the secondary antibody at a concentration of 1:8,000. Membranes were developed with ECL Western Blotting Detection Reagents (Amersham Biosciences) or TMB Membrane Peroxidase Substrate (KPL, Gaithersburg, MD).

Identification of the MrkH binding site in the mrkA regulatory region
Because of the high degree of conservation between the various components of the RNA polymerases of K. pneumoniae and E. coli (http://ecocyc.org), analysis of transcriptional regulation of K. pneumoniae genes can be conveniently carried out in E. coli [9,10,42]. Furthermore, sequence analysis of E. coli genomes confirmed the absence of any sequences that could encode MrkH homologous. Using the E. coli K12 strain MC4100, we sought to map the MrkH binding site, and generated four PCR fragments of the mrkA regulatory region: from positions 284, 277, 271 or 267 to +166, relative to the start site of transcription ( Fig. 1 and Table 1). These four fragments were each ligated into the single copy plasmid pMU2385 [10] to create mrkA-lacZ transcriptional fusions (mrkA-lacZ-2-5). The resulting pMU2385 derivatives, along with the previously constructed mrkA-lacZ-1 fusion (-91 to +166), were each transformed into E. coli MC4100 containing either the control plasmid pACYC184 (MrkH 2 background), or the plasmid pMrkH (MrkH + background) [10]. b-galactosidase levels were assessed for each of the transformants grown in LB at 37uC.
As shown in Table 1, the construct mrkA-lacZ-1 (291 to +166) expressed 10 U and 3886 U of b-galactosidase activities in the MrkH 2 and MrkH + backgrounds, respectively, which represents 388-fold activation of mrkA expression by the MrkH protein. The very low levels of b-galactosidase activity in the MrkH 2 background suggests that there exists no endogenous E. coli proteins that can induce mrkA expression. While mrkA-lacZ-2 (284 to +166) exhibited the same level of MrkH-mediated activation as that of mrkA-lacZ-1, the expression of three other deletion mutants (mrkA-lacZ-3, mrkA-lacZ-4 and mrkA-lacZ-5) were not activated by MrkH. These results indicate that the region immediately downstream from position 284 contains the mrkA operator. Sequence analysis of this region revealed a 12-bp palindromic sequence between positions 284 and 273 (Fig. 1). To determine whether this sequence, which we named the 'MrkH box', is important for MrkH-mediated activation of mrkA transcription, we made a mrkA regulatory region mutation in which the DNA sequence of the MrkH box was scrambled (Fig. 1). A bgalactosidase assay showed that the MrkH box mut-1 mutation caused a complete loss of mrkA transcription activation (Table 1).  To further confirm that the MrkH box is responsible for MrkH binding, we carried out an electrophoretic mobility shift assay (EMSA). Two 32 P-labelled mrkA-promoter DNA fragments which contain the wild-type and the mutant MrkH boxes were each mixed with varying concentrations of the purified MrkH-86His protein in the presence of c-di-GMP for 20 min at 30uC, after which the samples were analyzed on native polyacrylamide gels. The results in Fig. 2 show that the wild-type MrkH box DNA, but not the mutant mrkA fragment, is recognized by MrkH to form a protein-DNA complex, indicating that the MrkH box sequence is critical for MrkH to bind to the mrkA regulatory region.
To evaluate the contribution of the nucleotides within the MrkH box to transcriptional activation of the mrkA promoter by MrkH, we made a series of double-base changes in the MrkH box (Fig. 3). b-galactosidase analysis showed that all of the operator mutations significantly affected MrkH-mediated activation. While five of these mutants (MrkH box mut-2, 3, 4, 7 and 8) exhibited a relatively small reduction in the levels of MrkH-mediated activation of mrkA expression (to 30-56% of the wild-type mrkA-lacZ level), the other two (MrkH box mut-5 and 6) which carry base changes in the center of the MrkH box had a stronger effect on activation by MrkH (10-13% of the wild-type mrkA-lacZ level) (Fig. 3). DNA fragments containing these two mutations (MrkH box mut-5 and 6) were analyzed by EMSA and the data in Fig. S1 confirmed that the mutant DNA fragments had a marked decrease in the affinity for the MrkH protein.

Mutational analysis of the mrkA promoter
The mrkA promoter is composed of an imperfect 235 element (TTAATG) and a suboptimal spacer (15 bp) [10], which would explain the very weak mrkA promoter activity in a MrkH 2 background ( Fig. 1 and Table 2). To test whether the mechanism of MrkH action is to correct the mrkA promoter defects arising from its suboptimal core elements, we constructed a 'promoter-up' mutation, in which the 235 element was altered to the consensus sequence (TTGACA), and the spacer region increased to the optimum length of 17 bp (Fig. 1). The transcriptional activity of the mutant promoter (Promoter-up) was then compared with that of the wild-type mrkA promoter. In the MrkH 2 background, the Promoter-up mutation caused a large increase in promoter activity, from 11 U to 3379 U ( Table 2). In contrast, in the MrkH + background, the mutant promoter had only a minor enhancement of transcriptional activity, from 4371 U to 5414 U ( Table 2). The observation that the wild-type, but not the Promoter-up mutant mrkA promoter, required MrkH for maximal expression supports the hypothesis that MrkH functions to enhance the weak interaction between RNA polymerase and the wild-type mrkA promoter.
To investigate whether the MrkH-mediated activation of mrkA expression involves an interaction between MrkH and RNA polymerase (RNAP), we made two deletion mutations (D5 and D10) in the mrkA regulatory region (Fig. 1). Functional analysis of these mutations showed that, whereas deleting a full turn of DNA helix (10-bp; D10) between the MrkH Box and the mrkA promoter core elements had little effect on MrkH-mediated activation, removing half a turn of DNA helix (5-bp; D5) rendered the mrkA promoter insensitive to activation by MrkH. This ''face-of-thehelix'' specificity for maximal activation is consistent with the conclusion that an interaction between MrkH and RNAP occurs and that such interaction requires a proper alignment of the two proteins on the mrkA promoter region. Similar face-of-the-helix effects were also seen for the CRP-mediated activation of its target promoters [43,44].
The mrkA upstream region contains an AT-rich cluster centered at 263.5, which could function as an UP element [45] for mrkA transcriptional initiation (Fig. 1). To determine if this AT-rich cluster plays any role in mrkA transcription, we replaced four AT pairs by GC pairs within this 10-bp sequence (UP mutation) (Fig. 1). While, in comparison with the wild-type promoter, this mutation exhibited no change in transcription levels in the MrkH 2 background, the activity of the mutant promoter was decreased to 252 U in the MrkH + background, representing a major reduction in the degree of mrkA transcription (from 397-fold to 23-fold). These results clearly showed that the AT-rich cluster centered at 263.5 is involved in MrkH-mediated activation of mrkA transcription. Furthermore, an EMSA experiment showed that, similar to the wild-type mrkA fragment, MrkH was able to completely shift the mutant mrkA fragment (UP mutation) at 300 nM (Fig. S2), indicating that this AT-rich cluster is not important for MrkH binding.

qrt-RT-PCR analysis of promoter and operator mutations of mrkA
To confirm the effect of the mrkA promoter and operator mutations in K. pneumoniae, we carried out qrt-RT-PCR analysis. To do this, three pMU2385 derivatives containing different mrkA fragments (wild-type, Promoter-up and MrkH box mut-1) were each introduced into a DmrkH mutant K. pneumoniae strain carrying either pACYC184 (MrkH 2 ) or pMrkH (MrkH + ). Following growth of the various K. pneumoniae strains to mid-log phase, total cellular RNA was isolated from each of these strains and the mrkA transcripts encoded by the pMU2385 derivatives was probed by using primers mrkA15F and pMU2385Rev. The levels of expression from each sample were normalized to the reference Regulation of the mrkA Promoter by MrkH PLOS ONE | www.plosone.org gene rpoD and the relative abundance of transcripts from the MrkH 2 and MrkH + backgrounds was assessed. As shown in Table 3, the transcription of the wild-type mrkA promoter was upregulated 637-fold in the MrkH + background compared with the value in the MrkH 2 background. In contrast, less than 2-fold activation by MrkH was detected for the mrkA promoter mutant (Promoter-up) and no significant activation by MrkH was seen for the mrkA operator mutant (MrkH box mut-1). These results are in agreement with those obtained by b-galactosidase assays (see above).

RNAP and positive control of the mrkA promoter
Three observations collectively implicate a role for the Cterminal domain of the a subunit (a-CTD) of RNA polymerase in the positive control of the mrkA promoter: (i) the upstream location of the MrkH box, (ii) the ''face-of-the-helix'' specificity of MrkHmediated activation, and (iii) the presence of a putative UP element in the mrkA promoter. To test this hypothesis, we investigated whether overexpression of rpoA mutations affected MrkH-mediated activation of mrkA expression. Plasmid pLAW2 [46] which carries the wild-type E. coli rpoA gene (under the control of the lpp/lacUV5 promoter) and a set of pLAW2 derivatives, in which the rpoA gene contains alanine substitutions at positions 258 to 275, were each transformed into E. coli strain MC4100 containing pMrkH and the wild-type mrkA-lacZ fusion pMU2385 derivative (mrkA promoter positions 2190 to +166). b-galactosidase assays showed that overexpression of the a subunit variants R265A, S266A, L270A, E273A and I275A led to a significant reduction of the MrkH-dependent mrkA expression (Fig. 4A). Moreover, Western blot analysis showed that MrkH was efficiently expressed in the MC4100 backgrounds over-expressing either the wild-type or each of the five mutant a subunits (Fig. S3). These results suggest that the residues at these positions of the wild-type a-CTD are involved in the MrkH-mediated transcriptional activation of the mrkA promoter.

A positive control mutation in MrkH
Although the central region of MrkH is known to contain conserved residues within the PilZ domain that are responsible for   c-di-GMP binding and MrkH function [10,11,12] (Fig. 5A), the transcriptional activation and DNA-binding domains of MrkH have not yet been identified. Analysis of the secondary structure of MrkH using several algorithms revealed the presence of an a-helix and several b-sheets at both the N-terminus and C-terminus of the protein.
To characterize these two regions, we generated four mutations where alanine and serine (AS) residues were inserted into a1, b2, b10 and a2 (Fig. 5A). Insertion mutagenesis of AS was used to characterize the a subunit of the E. coli RNA polymerase and the RegA regulator of C. rodentium as insertion of these amino acids does not cause major perturbation in the overall structure of proteins [47,48].
In vivo transcriptional analysis showed that disruption of b2 (39AS40) had little effect on MrkH-mediated activation of mrkA expression (Fig. 5B), indicating that the b2 region of MrkH is not involved in DNA-binding or the possible interaction with RNA polymerase. In contrast, the amino acid insertions into a1, b10 and a2 (15AS16, 202AS203 and 217AS218) rendered the MrkH protein completely defective in transcriptional activation (Fig. 5B). Western blot analysis showed the mutant proteins to be stably expressed (Fig. S4). To further characterize the four mutations, they were each purified as C-terminal 86His-tag proteins. EMSA analysis using a 32 P-labelled wild-type mrkA fragment and each of the mutant MrkH proteins showed that, whereas 15AS16 and 39AS40 retained DNA-binding activity, 202AS203 and 217AS218 were unable to interact with the DNA target (Fig. 5C). This suggests that the N-terminal tip of the MrkH protein is responsible for the positive control of the mrkA promoter and the C-terminal region is either directly or indirectly involved in DNA-binding. The ability of the four mutant MrkH constructs to mediate biofilm formation via type 3 fimbriae expression in K. pneumoniae was also assessed. In agreement with the data from the transcriptional analysis as shown in Fig. 5B, mutation of the a1, b10 and a2 regions resulted in the loss of biofilm formation and type 3 fimbriae expression, while disruption of b2 caused little change in were each transformed into E. coli strain MC4100 containing plasmids mrkA-lacZ(2190 to +166) and pMrkH. The b-galactosidase activities of the various samples (from three independent experiments) are presented relative to the activity of the strain carrying the plasmid pLAW2 containing wild-type rpoA. Grey bars correspond to those alanine replacements that result in a reduction of at least 20% of b-galactosidase activity. Error bars indicate standard deviation of the mean. Data are representative of three independent experiments. Statistical significance between wild-type and alanine mutants was analysed by Student's t-test, where *** = P,0.001, ** = P,0.01, * = P,0.05. (B) The structure of a-CTD of RNAP [52,59] is shown and the surface-exposed residues R265 (red) and E273 (blue) are marked. doi:10.1371/journal.pone.0079038.g004 the ability of MrkH to promote high levels of biofilm formation and type 3 fimbriae expression (Fig. 5D & E).

Discussion
The data obtained from the present study revealed the mechanism by which the MrkH protein controls the expression of the mrkA promoter, a key point of regulation that is critical for the switch between planktonic growth and biofilm formation of K. pneumoniae. The mrkA promoter is essentially transcriptionally inactive in the MrkH 2 background (Table 2) or in a K. pneumoniae strain that is defective in c-di-GMP synthesis [10,11,12]. The extremely low level basal activity of the promoter is attributed to the presence of a suboptimal 235 region (the sequence TTAATG versus the consensus TTGACA) and a shorter spacer (15-bp versus 17-bp) within the promoter core sequence. The 235 and the 210 hexamers are known to directly interact with amino acid residues within regions 4.2 and 2.4, respectively, of the s 70 subunit of RNAP [49,50], therefore the base composition and a proper alignment of the two elements are critical for RNAP binding. Consistent with this model, inserting a consensus sequence in the 235 hexamer and increasing the length of the spacer (Promoterup mutation) led to greater than 300-fold enhancement of the transcriptional activity of mrkA (Table 2).
Two cis-acting elements, a 12-bp palindromic sequence (the MrkH box) and a 10-bp AT-rich cluster (UP element) centered at 278.5 and 263.5, respectively, are important for MrkH-mediated activation of mrkA expression. Results from EMSA experiments indicate that the MrkH box is responsible for MrkH binding. Palindromic DNA sequences attract DNA-binding proteins in a dimer formation [51], suggesting that MrkH binds to its DNA target as a dimer. However, further biophysical analysis of the MrkH protein is required to test this model.
The ''face-of-the-helix'' effect between the MrkH box and the mrkA promoter core sequence demonstrated by deletion mutagenesis suggests a direct interaction between MrkH and RNAP. Using a set of E.coli rpoA variants that carry alanine replacements in the a-CTD of RNAP (the a-CTD of E. coli is identical to that of K. pneumoniae, http://ecocyc.org), we identified 5 residues (R265, S266, L270, E273 and I275) that are required for MrkH-mediated activation of mrkA expression. Based on the crystal structure of the a-CTD of RNAP [52], R265 and E273 are exposed on the surface of the a-CTD (Fig. 4B), while the other three residues are buried inside the structure and mutations in these three positions may impact indirectly on residues contacting MrkH. Conversely, the surface-exposed residues R265 and E273 are prime candidates to be directly involved in making contact with DNA and/or with the MrkH protein.
R265 has been shown to directly interact with the UP elements of many bacterial promoters [53,54]. An elegant NMR study by Ishihama and Kyogoku groups showed that the guanidino group of R265 of the a-CTD interacts with the negatively charged phosphate backbone within the DNA minor groove of an UP element [55]. If R265 also contacts the UP element of the mrkA promoter, this interaction appears to contribute significantly to the MrkH-dependent transcription initiation of the mrkA promoter, as replacing AT pairs by GC pairs within the UP element led to a 17fold reduction of the promoter activity in the MrkH + background ( Table 2). In the context of RNAP binding to the proP P2 promoter in E. coli, E273 has been shown to interact with the regulatory protein Fis [56]. Mutational analysis of the mrkH gene showed that its short N-terminal arm is involved in transcriptional activation of the mrkA promoter. However, detailed genetic, biochemical and structural studies are required to establish the mechanism of interaction between MrkH and RNAP.
Based on the results of this study, we propose that MrkH functions as a Class I transcriptional activator at the mrkA promoter [57,58]. Upon binding the MrkH box (in the presence of c-di-GMP) and through an interaction with the a-CTD, MrkH enhances the binding of RNAP to the UP and the core elements of the mrkA promoter, thereby stimulating the rate of transcription initiation (Fig. 6). Using this regulatory mechanism, K. pneumoniae is able to rapidly drive the production of type 3 fimbriae under desirable environmental conditions, leading to the rapid formation of biofilms. Figure S1 EMSA analysis of the binding of purified MrkH-86His to the mrkA fragment mutated in the MrkH box. 32 Figure S3 Western blot analysis of MrkH expression in E. coli strain MC4100. MrkH was expressed as a C-terminal MrkH-86His fusion from the plasmid pACYC184-mrkH-86His in MC4100 which also carried a pLAW2 derivative expressing the wild-type or each of the mutant a subunits of RNAP (R265A, S266A, L270A, E273A and I275A). The MC4100 derivate carrying pACYC814 and pLAW2(WT rpoA) was used as the negative control. The induction of the different rpoA alleles was as described in the legend to Fig. 4. Western blot of MrkH-86His was performed using a-His antibody. (TIF) Figure S4 Western blot analysis of MrkH expression in E. coil strain MC4100. Wild-type and mutant forms of MrkH-86His were expressed from pACYC184 in MC4100. Samples were prepared by sonication followed by centrifugation and supernatants were separated by SDS-PAGE. Following transfer, the membrane was probed with a-His antibody. E. coli MC4100 harboring empty pACYC184 was used as the negative control. (TIF) Acknowledgments T.L. is an ARC Federation Fellow, C.T.W. is an NHMRC Postdoctoral Fellow. We thank Prof. A. Ishihama for plasmid pLAW2 and its derivatives.